SRPTSarepta Therapeutics, Inc.

The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.

Revenue fell 34% YoY as management narrows guidance and eyes 2027 growth.

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

Sarepta Therapeutics (SRPT) is seeing a new strategic focus under its recently appointed CEO, with m

Sarepta Therapeutics Inc (SRPT) reports Q2 2026 GAAP operating income of $13 million and advances siRNA pipeline while navigating Elevidys revenue challenges.

Sarepta Therapeutics (NASDAQ:SRPT) reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating income of $13 million and non-GAAP operating income of $86 million, while increasing

Moby summary of Sarepta Therapeutics, Inc.'s Q2 2026 earnings call

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Arrowhead Pharmaceuticals Inc (ARWR) reports robust clinical progress and commercial growth, despite a wider net loss in Q3 2026.

Sarepta Therapeutics (SRPT) has drawn fresh attention after filing a US$39.7 million shelf registration tied to an employee stock ownership plan, alongside appointing Michael Severino, M.D., as its new Chief Executive Officer. See our latest analysis for Sarepta Therapeutics. The CEO transition and fresh equity capacity come after a period where Sarepta Therapeutics’ share price has fallen 30.9% over the past three months and 30.3% year to date, while the 3 year total shareholder return is...

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Legend Biotech’s CEO stepped down without warning, while Sarepta has appointed a biopharma veteran to take the company forward.

Morgan Stanley said it remains cautious in the near term because of continued challenges in the company's Duchenne muscular dystrophy business.

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.

With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.

Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients.

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.

FDA sNDA Acceptance Puts Sarepta Therapeutics Stock in Focus Sarepta Therapeutics (SRPT) recently reported that the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, seeking conversion from accelerated to traditional approvals in Duchenne muscular dystrophy. This regulatory step, backed by Phase 3 ESSENCE data and real world evidence on efficacy trends and safety, gives investors a new reference point for evaluating Sarepta Therapeutics stock and its Duchenne...

In June 2026, Sarepta Therapeutics announced that the FDA accepted supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy exon-skipping therapies AMONDYS 45 and VYONDYS 53 to traditional approvals, with a PDUFA action date set for February 28, 2027. This move, backed by the ESSENCE confirmatory study and extensive real-world evidence across more than 1,800 treated patients, could be important for reinforcing the long-term regulatory footing of...

The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.